| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 19.02 | 5411 |
| Intrinsic value (DCF) | 0.62 | 80 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Silo Pharma, Inc. (NASDAQ: SILO) is a developmental-stage biopharmaceutical company pioneering innovative therapeutics for underserved medical conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company leverages both traditional and psychedelic-based treatments, focusing on novel drug delivery systems to enhance efficacy and patient compliance. Its lead candidate, SPC-15, is an intranasal formulation targeting PTSD and stress-induced anxiety, while SP-26 is a time-release ketamine implant for fibromyalgia and chronic pain. Silo Pharma also has preclinical programs like SPC-14 for Alzheimer’s and SPU-16 for multiple sclerosis. Collaborating with leading institutions such as Columbia University and the University of Maryland, Baltimore, Silo Pharma combines cutting-edge research with strategic partnerships to advance its pipeline. Headquartered in Sarasota, Florida, the company operates in the high-growth biotechnology sector, positioning itself at the intersection of mental health innovation and next-generation CNS therapies.
Silo Pharma presents a high-risk, high-reward investment opportunity given its early-stage pipeline and focus on underserved CNS and psychiatric conditions. The company’s collaborations with prestigious academic institutions lend credibility, but its developmental-stage status means significant clinical and regulatory risks remain. With no commercialized products, revenue is minimal ($72K in latest reporting), and net losses are substantial (-$4.4M). The lack of debt is a positive, and its $3.9M cash position provides some runway, but dilution risk is high given its micro-cap status ($3.1M market cap) and reliance on equity financing. Investors should monitor clinical progress, particularly for SPC-15 (PTSD) and SP-26 (chronic pain), as positive data could catalyze upside. However, the stock’s high beta (1.49) reflects volatility, making it suitable only for speculative investors comfortable with biotech sector risks.
Silo Pharma competes in the niche but rapidly evolving psychedelic and CNS therapeutics space, where differentiation hinges on intellectual property, delivery mechanisms, and clinical validation. Its intranasal and implant-based delivery systems (e.g., SPC-15, SP-26) could offer advantages over oral or IV therapies in compliance and bioavailability. However, the company faces intense competition from larger biotechs and pharma firms with deeper pipelines and resources. Its focus on PTSD, fibromyalgia, and Alzheimer’s aligns with high unmet needs, but these are crowded markets with candidates in late-stage trials from established players. Silo’s academic partnerships are a strength, but scalability remains unproven. The lack of revenue-generating products and reliance on preclinical/early-stage assets heighten risk compared to peers with commercialized therapies. While its micro-cap size allows agility, it also limits bargaining power in potential partnerships or M&A. Success will depend on achieving clinical milestones ahead of competitors and securing non-dilutive funding.